{"schema_version":"secwatch.filing_event.v1","accession":"0001639691-25-000146","form_type":"8-K","ticker":"LIVN","cik":"0001639691","company_name":"LivaNova PLC","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.020526+00:00","generated_at":"2026-05-17T00:18:29.917614+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"LivaNova Q3 revenue $357.8M (+12.5% organic); raises FY2025 EPS guidance to $3.80-$3.90","bullets":["Third-quarter revenue $357.8M, up 12.5% reported, 11% constant-currency, and 12.5% organic vs prior year.","GAAP diluted EPS $0.49; adjusted diluted EPS $1.11.","Raised FY2025 guidance: revenue growth 8.5%-9.5% constant currency, EPS $3.80-$3.90, FCF $160M-$180M.","Initiated commercial launch of Essenz Perfusion System in China, the second-largest heart-lung machine market.","Appointed Donald Zurbay to the Board of Directors and Audit and Compliance Committee."],"urls":{"canonical":"https://secwatch.observer/filing/0001639691-25-000146","json":"https://secwatch.observer/filing/0001639691-25-000146.json","markdown":"https://secwatch.observer/filing/0001639691-25-000146.md","text":"https://secwatch.observer/filing/0001639691-25-000146.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1639691/000163969125000146/0001639691-25-000146-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1639691/000163969125000146/livn-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:18:29.917614+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}